key: cord-0964547-c82i3u0j authors: Rodriguez, Lucie; Pekkarinen, Pirkka T.; Lakshmikanth, Tadepally; Tan, Ziyang; Consiglio, Camila Rosat; Pou, Christian; Chen, Yang; Mugabo, Constantin Habimana; Nguyen, Ngoc Anh; Nowlan, Kirsten; Strandin, Tomas; Levanov, Lev; Mikes, Jaromir; Wang, Jun; Kantele, Anu; Hepojoki, Jussi; Vapalahti, Olli; Heinonen, Santtu; Kekäläinen, Eliisa; Brodin, Petter title: Systems-level immunomonitoring from acute to recovery phase of severe COVID-19 date: 2020-08-05 journal: Cell Rep Med DOI: 10.1016/j.xcrm.2020.100078 sha: 688e909618cb2b0162cd43f64079a6aa320652dc doc_id: 964547 cord_uid: c82i3u0j Summary Severe disease of SARS-CoV2 is characterized by vigorous inflammatory responses in the lung, often with a sudden onset after 5-7 days of stable disease. Efforts to modulate this hyperinflammation and the associated acute respiratory distress syndrome, rely on the unraveling of the immune cell interactions and cytokines that drive such responses. Given that every patient is captured at different stages of infection, longitudinal monitoring of the immune response is critical and systems-level analyses required to capture cellular interactions. Here we report on a systems-level blood immunomonitoring study of 37 adult patients diagnosed with COVID-19 and followed with up to 14 blood samples from acute to recovery phases of the disease. We describe an IFNγ – Eosinophil axis activated prior to lung hyperinflammation and changes in cell-cell coregulation during different stages of the disease. We also map an immune trajectory during recovery that is shared among patients with severe COVID-19. (Olink assays) IFNγ CD62L+ eosinophil Since its emergence in December 2019 the severe acute respiratory syndrome-54 corona virus 2 (SARS-CoV2) causing the disease COVID-19 has infected 55 millions of individuals and caused hundreds of thousands of deaths worldwide. 56 The betacoronavirus has high degree of sequence homology with previous 57 SARS-CoV and MERS coronaviruses and binds to the angiotensin-converting 58 enzyme 2, ACE2-receptor to enter cells in the respiratory and intestinal epitelium 59 1 . 60 61 Cells recognize the presence of the virus through pathogen recognition 62 receptors, PRR and elicit antiviral response programs 2 . The two main 63 components of such antiviral programs involve the production of type I and III 64 6 the first week after admission in these patients (Fig. 3) . The recovery of T-cells 158 after the initial lymphopenia occurs over the following 2-3 weeks and is 159 dominated by CD127 expressing effector and central memory CD4 + T-cells, as 160 well as CD57-expressing and differentiated memory CD8 + T-cells (Fig. 3) . Also, 161 all Dendritic cell (DC) subsets increased from acute to recovery phases, CD1c + 162 DCs, CD11c + DCs and plasmacytoid DCs (pDC) (Fig. 3) . Also, despite a clear 163 reduction in the relative abundance of neutrophils over time, the other 164 granulocyte subsets, basophils and eosinophils increased clearly from acute to 165 recovery phases (Fig. 3) , and both of these were among the most dynamic cell Given the changes in eosinophil abundance above, we decided to study 171 eosinophils more carefully. There are reports of strong GM-CSF responses in 172 lungs of COVID-19 patients 14 and GM-CSF is known to stimulate eosinophils, 173 particularly in interstitial pneumonia and allergic inflammation 15 . Taking 174 advantage of the detailed longitudinal sample series, we used Partition-based 175 graph abstraction, PAGA 16 , to reconstruct single-cell phenotypic changes of 176 blood eosinophils during acute COVID-19 (Fig. 4) . Leiden clustering found 12 177 eosinophils subsets and the main groups are annotated by defining features (Fig. 178 4A). By splitting cells obtained from the different longitudinal samples, time-179 associated changes in eosinophil phenotypes are revealed with a transient 180 expansion of CD62L + eosinophils from day 2 to day 6 after admission (Fig. 4B) . 181 CD62L-upregulation on eosinophils have been reported to be induced by IFNγ 17 , 182 one of the most elevated cytokines in severe COVID-19, and the IFNγ levels 183 show a slight increase right around the same time as the expansion of CD62L+ 184 eosinophils (Fig. 4C) . This phenotype of eosinophils is reminiscent of lung 185 resident eosinophils, rather than induced inflammatory eosinophils in circulation 186 and such lung-homing cells have previously been reported as important 187 homeostatic regulators of inflammatory responses in the lung 18 (Fig. 4D) . It is 188 7 tempting to think that this transient expansion of CD62L+ eosinophils just prior to 189 the time development of severe lung hyperinflamation around 1 week after 190 admission is related to this immunopathology of the lungs in To this end further investigation into this eosinophil -IFNγ axis is required and 192 might suggest novel therapies targeting this response to mitigate ARDS and lung immune cell responses in our cohort we used the same PAGA approach as 203 described above. We find a clear plasmablasts response early after admission 204 (Fig. 5A) . The CD4 + T-cell response were initially dominated by effector and 205 central memory responses, followed by an increase in Tregs approximately four 206 days after admission (Fig. 5B) . The CD4 + T-cells were split into two effector cell 207 populations based CD4-expression level, possible reflecting an activation-208 induced downregulation in a subset of CD4 + T-cells (Fig. 5B) 22 . The CD8 + T-cell 209 responses are dominated by activated cells expressing high CD38 and also a 210 subset of effector cells upregulating the CD147 receptor from about one week 211 onwards (Fig. 5C) . Gamma-delta TCR T-cells, (γδT-cells) and CD8 + T-cells 212 progressively upregulated the marker of terminal maturation CD57 from about 1 213 week onwards (Fig. 5C-D) . These results are largely in agreement with other 214 recent reports 23 and highlight the strong innate and adaptive immune activation 215 during acute COVID-19. and other mediators. By studying such cell-cell relationships a better 221 understanding of the systems-level response can be obtained. We generated 222 cell-cell correlation matrices using longitudinal cell population frequencies and 223 binned the samples into four phases from acute disease to recovery phase (Fig. 224 6A) . We find that the first phase (day 0-4) is dominated by an inverse correlation 225 between neutrophils and a number of myeloid and lymphoid cell types, as 226 reflected in the elevated NLR, associated with severe disease 12 (Fig. 6A) . The 227 following phase (day 6-8) is characterized by a strong coordinated plasmablast, 228 B-cell and αβT-cell module, and this is inversely correlated with a strong Treg 229 and CD11c + DC module (Fig. 6A) . From day 9 onwards a change is apparent 230 with a shift towards a coregulated module involving eosinophils, pDCs, CD11c + 231 DCs, with CD8 + T-cells. This module is largely maintained in the recovered 232 patients, possibly reflecting a more normal cell-cell relationship (Fig. 6A) . 233 234 A prototype of a coordinated immune response to viruses is the appearance of 235 virus specific IgG antibodies because such responses elicited by B-cells require 236 help from CD4 + T-cells. Here we investigated the seroconversion in this cohort 237 and found strong induction of IgG antibodies to the SARS-CoV2 Spike protein 238 (Receptor Binding Domain, RBD) in the majority of patients (Fig. 6B) . This is in 239 line with similar analyses in other COVID-19 patients 2024 . We were unable to test 240 the neutralizing capacity of these antibodies at this time, but another recent 241 report has shown that a significant proportion of patients mount antibodies that 242 lack such neutralizing capacity 21 . To understand the immunological correlates of 243 IgG responses to SARS-CoV2, we devised a mixed effect model, using both 244 plasma protein levels and cell frequencies as predictors, taking days after 245 admission into account as a fixed effect 25 . It is important to note that this is not a 246 simple correlation analysis since days from admission is taking into account as a 247 fixed effect in the analysis. We found several features significantly associated 248 with IgG-responses and in particular strong proinflammatory cytokines IFNγ, IL-6, 249 and chemokines CXCL10 and MCP-2 (CCL8) are negatively associated with 250 anti-CoV2 IgG responses (Fig. 6C) . In contrast the neutrophil-recruiting 251 chemokine CXCL6 are positively associated with anti-CoV2 IgG responses and 252 so was the fraction of circulating Basophils (Fig. 6C) . It is known that basophils 253 are able to bind antigens on their surface and potentiate humoral immune 254 responses 26 and since basophils are depleted during acute and severe COVID-255 19 (Fig. 3) , our data collectively suggest that the degree of basophil depletion 256 might influence the efficacy of IgG-responses to SARS-CoV2. It is believed that 257 basophil mediated enhancement of B-cell responses occurs through the 258 production of either IL-4 or IL-6, but levels of the latter were found to be inversely 259 associated with antibody responses (Fig. 6C ) so it is more likely that another We found ten latent factors that explained the variance in the combined dataset 280 (Fig. 7A) , and out of those, latent factor 2 was associated with the transition from 281 acute to recovery phases of disease (Fig. 7B ). There were no clear differences 282 among intensive care unit (ICU) or non-ICU ward patients and the levels of latent 283 factor 2 were highest in the samples taken from recovered patients (Fig. 7B) . To 284 understand the biology of immune recovery we assessed the underlying features 285 contributing to latent factor 2. The plasma proteins changing the most all 286 decreased during recovery and most prominent were IL-6, MCP3, KRT19 287 (Keratin19), CXCL10, AREG and IFNγ (Fig. 7C) . Conversely the cells that 288 changed the most during recovery were classical and non-classical monocytes, 289 This study has several limitations. First we performed longitudinal systems-level 394 immunomonitoring of acute and recovered COVID-19 patients but due to 395 logistical limitations in the overwhelmed hospital wards, we were unable to collect 396 longitudnal samples for recovered patients and were also limited in the number of 397 acute COVID-19 disease patients we could enroll. We were unable to include a 398 healthy cohort and unfortunately we were not powered to robustly compare 399 patients in ICU vs. non-ICU with respect to their immunological trajectories. Further information and requests for resources and reagents should be directed 485 to and will be fulfilled by the Lead Contact, Petter brodin (petter.brodin@ki.se). 486 This study did not generate new unique reagents. 488 The raw mass cytometry data and the Olink protein data generated during this 490 study are available for download on our lab webpage (https://brodinlab.com/data-491 repository/). The IgG data is presented in Suppl. We included symptomatic patients with positive SARS-CoV-2 PCR test admitted 498 to Helsinki University Hospital, Helsinki, Finland. Patients were recruited within 499 five days after hospitalization. We excluded patients who had been considered 500 by the attending clinician not to benefit from intensive care. The clinical decisions 501 were based on comorbidities and general frailty, not the severity of the COVID-19 502 disease. We recruited 17 inpatients (9 females, 8 males) aged between 40 -77 503 years. The duration of hospitalization ranged from 5 to 38 days. Of these, 10 504 were admitted to the ICU, and remained in intensive care for 1 -27 days. Three 505 patients required mechanical ventilation for 3, 13 and 19 days, respectively. 506 507 In addition to patients recruited during the acute phase of illness, we recruited a 509 separate cohort of recovered patients based on positive PCR (n=20). Of this 510 recovered cohort, there were 18 mild COVID-19 patients and 2 hospitalized 511 COVID-19 patients. These 20 subjects (age range 28 -68 years; 11 females, 9 512 males) were included during convalescence 3-4 weeks after COVID-19 diagnosis 513 and SARS-CoV-2 detection. These patients were identified from medical and 514 laboratory records, contacted by phone and invited to donate a blood sample. 515 Characteristics of all patients described in Suppl. Table 2 . Fig.1 and Suppl. Fig. 2 Genomic characterisation and epidemiology of 2019 novel coronavirus: 669 implications for virus origins and receptor binding Decoding the Patterns of Self and Nonself by the 671 Innate Immune System Shared and Distinct Functions of 673 Imbalanced host response to SARS-CoV-2 drives development 675 of COVID-19 Impaired type I interferon activity and inflammatory responses in 677 severe COVID-19 patients Immunology of COVID-19: current state of the science Why is COVID 19 so mild in children Gender Differences in Patients With COVID-19: Focus on Severity 684 and Mortality Clinical features of patients infected with 2019 novel coronavirus in 686 The biology of the cell -insights from mass cytometry Homogeneous 690 antibody-based proximity extension assays provide sensitive and specific detection of 691 low-abundant proteins in human blood Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive 693 protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-694 analysis Aberrant pathogenic GM-CSF+ T cells and inflammatory 698 CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus Interleukin 5 and granulocyte-macrophage colony-stimulating 701 factor levels in bronchoalveolar lavage fluid in interstitial lung disease PAGA: graph abstraction reconciles clustering with trajectory 704 inference through a topology preserving map of single cells Interferon-γ Increases CD62L Expression on Human Eosinophils Lung-resident eosinophils represent a distinct regulatory eosinophil 708 subset Targets of T cell responses to SARS-CoV-2 coronavirus in humans 710 with COVID-19 disease and unexposed individuals Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 713 patients Convergent Antibody Responses to SARS-CoV-2 Infection in 715 Convalescent Individuals Helper T cells down-718 regulate CD4 expression upon chronic stimulation giving rise to double-negative T cells Deep immune profiling of COVID-19 patients reveals patient 721 heterogeneity and distinct immunotypes with implications for therapeutic interventions A serological assay to detect SARS-CoV-2 seroconversion in 724 humans A Nondegenerate 726 Penalized Likelihood Estimator for Variance Parameters in Multilevel Models Basophils enhance immunological memory responses Multi Omics Factor Analysis-a framework for unsupervised 731 integration of multi omics data sets Pulmonary Vascular Endothelialitis, Thrombosis, and 733 Angiogenesis in Covid-19 Human immune system variation Variation in the Human Immune System Is Largely Driven by Non-739 Stereotypic Immune System Development in Newborn Children A global effort to define the human 743 genetics of protective immunity to SARS-CoV-2 infection 750 Eosinophils and Respiratory Viruses Basophils now enhance memory The potential danger of suboptimal antibody responses in 753 COVID-19 Is COVID-19 receiving ADE from other coronaviruses? Viruses within the Flaviviridae decrease CD4 expression and inhibit 757 HIV replication in human CD4+ cells A genome-wide transcriptomic analysis of protein-coding genes in 759 human blood cells Serological and molecular findings during SARS-CoV-2 infection: 763 the first case study in Finland SARS CoV 2 Seroconversion in Humans: A Detailed Protocol 766 for a Serological Assay, Antigen Production, and Test Setup From Louvain to Leiden: guaranteeing 769 well-connected communities ForceAtlas2, a continuous 771 graph layout algorithm for handy network visualization designed for the Gephi software